Deep Bio said it signed a partnership with Visiopharm, a Danish pharmaceutical company, to supply DeepDx Prostate, its deep learning-based prostate cancer pathology image analysis software. Under the agreement, Deep Bio will be able to...

Join Visiopharm at USCAP 2017 and learn about how we are transforming pathology! Come see demonstrations of Analysis of PD-L1 and CD Markers within the Tumor Micro-Environment Visualize and quantify biomarker expression with heatmaps...

Visiopharm, the leading provider of quantitative digital pathology software for diagnostics and research, announces the launch of VIS 6.0-- a powerful new version of their software. VIS 6.0 includes many new features plus Engine™ a new...

The scanning of slides into whole slide images (WSI) is the just the first step on the journey of quantitative digital pathology; a journey in which hypotheses can be tested, derived and ultimately deliver both qualitative and quantitative...